
Innoviva Inc
INVAHealthcare|Biotechnology|USA
$22.23
+0.04 (+0.20%)
DCF (FCF)
$42.29
Tangible Book
$15.56
Graham Number
$41.06
Earnings Power
$26.78
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
440.56,
483.98,
511.61,
568.87,
641.11
],
"ebit_estimate": [
193.62,
207.16,
198.4,
199.04,
223
],
"ebitda_estimate": [
252.62,
254.8,
237.52,
null,
null
],
"net_income_estimate": [
317.23,
178.06,
184.14,
194.68,
218.96
],
"per_share_eps_estimate": [
3.87,
2.26,
1.79,
1.89,
2.09
],
"eps_nri_estimate": [
3.98,
2.24,
2.05,
1.89,
2.09
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
387.65,
220.95,
233.08,
246.44,
277.17
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
15.7,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
5.75,
9.82,
12.42,
11.76,
10.64
],
"long_term_growth_rate_mean": -18.16,
"long_term_revenue_growth_rate_mean": "7.77",
"future_per_share_eps_estimate_growth": -21.1,
"future_eps_nri_estimate_growth": -18.16,
"future_revenue_estimate_growth": 7.77,
"future_ebit_estimate_growth": 6.65,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -15.96,
"future_pretax_income_estimate_growth": -14.59,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
110.99,
113.48,
119.17,
119.28,
127.95,
127.1,
133.8
],
"ebit_estimate": [
51.61,
50.37,
51.86,
51.51,
54.2,
52.4,
53.9
],
"ebitda_estimate": [
69.65,
68.87,
65.91,
60.49,
null,
null,
null
],
"net_income_estimate": [
27.86,
40.69,
43.06,
44.42,
46.29,
44.79,
46.73
],
"per_share_eps_estimate": [
0.4,
0.5,
0.54,
0.56,
0.62,
0.61,
0.65
],
"eps_nri_estimate": [
0.44,
0.51,
0.54,
0.53,
0.61,
0.6,
0.64
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
32.89,
50.2,
53.13,
null,
null,
null,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
11.19,
10.05,
9.59,
9.17,
null,
null,
null
],
"long_term_growth_rate_mean": -18.16,
"long_term_revenue_growth_rate_mean": "7.77",
"future_per_share_eps_estimate_growth": -21.1,
"future_eps_nri_estimate_growth": -18.16,
"future_revenue_estimate_growth": 7.77,
"future_ebit_estimate_growth": 6.65,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -15.96,
"future_pretax_income_estimate_growth": -14.59,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}